Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once ...

Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new building in Kendall Square in 2028, consolidating its various branches and ...

Biogen inked a 15-year lease for a building at Cambridge’s Kendall Common that the company plans to christen as its new global headquarters in 2028.

Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. ... The three-story, 139,000-square-foot building is owned by Healthpeak Properties, ...

On the one hand, innovation can mean building new markets in therapeutic areas — as Biogen has always done in commercializing first-in-class drugs in rare disease or postpartum depression, for ...

Biogen plans to initiate five Phase 3 studies in 2025, ... emphasizing the extensive regulatory review as a confidence-building factor. Evan Seigerman, BMO Capital Markets: ...

Biogen has agreed to pay the young start-up $16 million up front and invest $30 million in the firm, ... City is building on that work by engineering new delivery vehicles for its cityRNAs, ...